Compare EWTX & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | LGIH |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.2B |
| IPO Year | 2021 | 2013 |
| Metric | EWTX | LGIH |
|---|---|---|
| Price | $23.71 | $48.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | $35.89 | ★ $71.13 |
| AVG Volume (30 Days) | ★ 1.2M | 325.7K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.53 |
| Revenue | N/A | ★ $1,788,933,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.77 |
| P/E Ratio | ★ N/A | $10.74 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.60 | $39.70 |
| 52 Week High | $35.50 | $104.31 |
| Indicator | EWTX | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 49.50 |
| Support Level | $23.13 | $46.73 |
| Resistance Level | $24.66 | $50.54 |
| Average True Range (ATR) | 1.32 | 2.27 |
| MACD | -0.31 | -0.27 |
| Stochastic Oscillator | 31.79 | 23.84 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.